RhumbLine Advisers’s CorMedix CRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $737K | Buy |
93,938
+8,227
| +10% | +$65K | ﹤0.01% | 2511 |
|
|
2026
Q1 | $582K | Sell |
85,711
-366
| -0.4% | -$2.71K | ﹤0.01% | 2514 |
|
|
2025
Q4 | $1M | Sell |
86,077
-9,475
| -10% | -$105K | ﹤0.01% | 2221 |
|
|
2025
Q3 | $1.11M | Buy |
95,552
+2,647
| +3% | +$32K | ﹤0.01% | 2189 |
|
|
2025
Q2 | $1.14M | Buy |
92,905
+11,340
| +14% | +$125K | ﹤0.01% | 2178 |
|
|
2025
Q1 | $502K | Buy |
81,565
+5,818
| +8% | +$60.2K | ﹤0.01% | 2574 |
|
|
2024
Q4 | $614K | Buy |
75,747
+6,028
| +9% | +$60.2K | ﹤0.01% | 2534 |
|
|
2024
Q3 | $563K | Sell |
69,719
-4,520
| -6% | -$24.5K | ﹤0.01% | 2624 |
|
|
2024
Q2 | $321K | Buy |
74,239
+11,339
| +18% | +$57.6K | ﹤0.01% | 2956 |
|
|
2024
Q1 | $267K | Sell |
62,900
-5,982
| -9% | -$20.7K | ﹤0.01% | 3041 |
|
|
2023
Q4 | $259K | Buy |
68,882
+12,186
| +21% | +$41.9K | ﹤0.01% | 3048 |
|
|
2023
Q3 | $210K | Buy |
56,696
+7,141
| +14% | +$28.4K | ﹤0.01% | 3137 |
|
|
2023
Q2 | $196K | Buy |
+49,555
| New | +$245K | ﹤0.01% | 3248 |
|
|
2022
Q2 | – | Sell |
-42,331
| Closed | -$232K | – | 3123 |
|
|
2022
Q1 | $232K | Sell |
42,331
-1,018
| -2% | -$4.66K | ﹤0.01% | 2723 |
|
|
2021
Q4 | $197K | Sell |
43,349
-7
| -0% | -$35 | ﹤0.01% | 2838 |
|
|
2021
Q3 | $202K | Buy |
43,356
+317
| +0.7% | +$1.85K | ﹤0.01% | 2912 |
|
|
2021
Q2 | $295K | Buy |
43,039
+18,488
| +75% | +$147K | ﹤0.01% | 2791 |
|
|
2021
Q1 | $245K | Sell |
24,551
-1,870
| -7% | -$19.7K | ﹤0.01% | 2772 |
|
|
2020
Q4 | $196K | Buy |
26,421
+6,081
| +30% | +$41.3K | ﹤0.01% | 2844 |
|
|
2020
Q3 | $123K | Sell |
20,340
-4,115
| -17% | -$20.7K | ﹤0.01% | 2829 |
|
|
2020
Q2 | $154K | Buy |
24,455
+4,993
| +26% | +$23.1K | ﹤0.01% | 2855 |
|
|
2020
Q1 | $70K | Hold |
19,462
| – | – | ﹤0.01% | 2833 |
|
|
2019
Q4 | $142K | Buy |
19,462
+132
| +0.7% | +$807 | ﹤0.01% | 2828 |
|
|
2019
Q3 | $123K | Buy |
19,330
+730
| +4% | +$6.13K | ﹤0.01% | 2851 |
|
|
2019
Q2 | $167K | Buy |
+18,600
| New | +$146K | ﹤0.01% | 2834 |
|
|
2016
Q2 | – | Sell |
-6,987
| Closed | -$93K | – | 2990 |
|
|
2016
Q1 | $93K | Buy |
6,987
+1,010
| +17% | +$9.8K | ﹤0.01% | 2906 |
|
|
2015
Q4 | $61K | Buy |
5,977
+618
| +12% | +$7.12K | ﹤0.01% | 2991 |
|
|
2015
Q3 | $53K | Buy |
5,359
+225
| +4% | +$3.47K | ﹤0.01% | 2990 |
|
|
2015
Q2 | $100K | Buy |
+5,134
| New | +$176K | ﹤0.01% | 3005 |
|
Other funds holding CRMD
DTC
RA
OAM
RhumbLine Advisers's CRMD Position: Q2 2026 in Review
RhumbLine Advisers increased its CorMedix (CRMD) stake by 9.6% in Q2 2026, buying an estimated $65K and bringing the position to 93,938 shares worth $737K. The position accounts for ﹤0.01% of the portfolio, ranked #2511.
RhumbLine Advisers first reported a position in CRMD in Q2 2015 and has held it in 29 quarters since. The position peaked at $1.14M in Q2 2025. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.
- RhumbLine Advisers held 93,938 shares of CorMedix worth $737K as of Q2 2026.
- RhumbLine Advisers bought 8,227 CorMedix shares in Q2 2026, an estimated $65K.
- CorMedix made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2511 holding.
- RhumbLine Advisers first reported a position in CorMedix in Q2 2015 and has held it in 29 quarters since.
- RhumbLine Advisers's CorMedix position peaked at $1.14M in Q2 2025.
- 193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.